Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C32H31N3O4 |
| Molecular Weight | 521.6062 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(C=C(NC2=CC=C(CCNC[C@H](O)C3=C4C=CC(=O)NC4=C(O)C=C3)C=C2)C=C1)C5=CC=CC=C5
InChI
InChIKey=LGFPFBZHAODPHC-LJAQVGFWSA-N
InChI=1S/C32H31N3O4/c1-39-30-15-11-24(19-27(30)22-5-3-2-4-6-22)34-23-9-7-21(8-10-23)17-18-33-20-29(37)25-12-14-28(36)32-26(25)13-16-31(38)35-32/h2-16,19,29,33-34,36-37H,17-18,20H2,1H3,(H,35,38)/t29-/m0/s1
| Molecular Formula | C32H31N3O4 |
| Molecular Weight | 521.6062 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 17:35:19 GMT 2025
by
admin
on
Tue Apr 01 17:35:19 GMT 2025
|
| Record UNII |
M37E3NE7QB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9871386
Created by
admin on Tue Apr 01 17:35:19 GMT 2025 , Edited by admin on Tue Apr 01 17:35:19 GMT 2025
|
PRIMARY | |||
|
530084-87-8
Created by
admin on Tue Apr 01 17:35:19 GMT 2025 , Edited by admin on Tue Apr 01 17:35:19 GMT 2025
|
PRIMARY | |||
|
DTXSID30432118
Created by
admin on Tue Apr 01 17:35:19 GMT 2025 , Edited by admin on Tue Apr 01 17:35:19 GMT 2025
|
PRIMARY | |||
|
M37E3NE7QB
Created by
admin on Tue Apr 01 17:35:19 GMT 2025 , Edited by admin on Tue Apr 01 17:35:19 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
TD-5471 (25), a potent and selective full agonist of the human .BETA.2-adrenoceptor, was identified as the most promising agent. It is potent, with slow onset in an in vitro guinea pig trachea model and shows a dose-dependent and long duration of action in an in vivo guinea pig model of bronchoprotection. TD-5471 is structurally differentiated from milveterol and its long duration of action is consistent with a correlation with hydrophobicity observed in other long-acting .BETA.2-agonist discovery programs.
|
||
|
ACTIVE MOIETY |
Originator: Theravance Biopharma; Mechanism of Action: Beta 2 adrenergic receptor agonist; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: No development reported for Asthma, Chronic obstructive pulmonary disease; Most Recent Event: 16 May 2016 Chemical information added
|